Metagenomi Investor Relations Material
Latest events
Study Update
Metagenomi
Q1 2025
13 May, 2025
Q4 2024
17 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Metagenomi Inc
Access all reports
Metagenomi Inc. is a biotechnology firm specializing in genetic medicines through its advanced metagenomics-derived genome editing technologies. The company leverages a proprietary toolbox that includes a variety of programmable nucleases, base editors, and RNA and DNA-mediated integration systems. These tools are designed to create precise and curative genetic therapies. Metagenomi focuses on developing these therapies to treat a range of serious diseases by harnessing naturally evolved microbial systems to enhance genome editing capabilities. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
MGX
Country
🇺🇸 United States